1. Oral Ibrexafungerp Outcomes in Subjects With Refractory Vulvovaginal Candidiasis From an Open-Label Study (FURI) [A122]. (May 2022) Authors: Goje, Oluwatosin; King, Thomas; Angulo, David; Azie, Nkechi Journal: Obstetrics and gynecology Issue: Volume 139(2022)Supplement 1 Page Start: 36S Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P056 Oral Ibrexafungerp outcomes by fungal disease in patients from an interim analysis of a Phase 3 Open-label Study (FURI). (20th September 2022) Authors: Prattes, Juergen; King, Thomas; Azie, Nkechi; Angulo, David Journal: Medical mycology Issue: Volume 60(2022)supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P057 All- cause mortality in patients with invasive Candidiasis or candidemia from an interim analysis of a Phase 3 Open-label Study (FURI). (20th September 2022) Authors: Prattes, Juergen; King, Thomas; Azie, Nkechi; Angulo, David Journal: Medical mycology Issue: Volume 60(2022)supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗